We are live on ! Find out more
O

OrbiMed Portfolio holdings

AUM $5.4B
1-Year Est. Return 163.13%
This Fund
S&P 500
This Quarter Est. Return
+9.12%
1 Year Est. Return
+163.13%
3 Year Est. Return
+393.16%
5 Year Est. Return
+486.34%
10 Year Est. Return
+3,312.73%
AUM
$5.39B
AUM Growth
-$132M
Cap. Flow
-$296M
Cap. Flow %
-5.49%
Top 10 Hldgs %
30.62%
Holding
156
New
15
Increased
31
Reduced
31
Closed
25

Top Buys

Rank Stock Value
1
THRD
Third Harmonic Bio
THRD
+$104M
2
SRPT icon
Sarepta Therapeutics
SRPT
+$90.6M
3
TMO icon
Thermo Fisher Scientific
TMO
+$49.7M
4
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$47.8M
5
BLU
BELLUS Health Inc.
BLU
+$33.8M

Top Sells

Rank Stock Value
1
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$168M
2
TPTX
Turning Point Therapeutics, Inc. Common Stock
TPTX
+$151M
3
SRRA
Sierra Oncology, Inc. Common Stock
SRRA
+$108M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$81.3M
5
GBT
Global Blood Therapeutics, Inc.
GBT
+$65.3M

Sector Composition

Rank Sector Weight
1 Healthcare 98.05%
2 Miscellaneous 1.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SYRE icon
126
Spyre Therapeutics
SYRE
$7.95B
$945K 0.02%
71,889
– –
VOR icon
127
Vor Biopharma
VOR
$1.32B
$445K 0.01%
5,590
-36,077
-87% -$3.55M
LBPH
128
DELISTED
Longboard Pharmaceuticals, Inc. Common Stock
LBPH
$422K 0.01%
113,500
– –
ABCL icon
129
CALL
AbCellera Biologics
ABCL
$3.68B
– –
-250,000
Closed -$2.66M
AMGN icon
130
Amgen
AMGN
$204B
– –
-57,100
Closed -$13.9M
CLDX icon
131
Celldex Therapeutics
CLDX
$3B
– –
-112,700
Closed -$3.04M
CTMX icon
132
CytomX Therapeutics
CTMX
$597M
– –
-2,124,975
Closed -$3.89M
ERAS icon
133
Erasca
ERAS
$5.54B
– –
-1,667,693
Closed -$9.29M
GH icon
134
CALL
Guardant Health
GH
$23.8B
– –
-50,000
Closed -$2.02M
GILD icon
135
Gilead Sciences
GILD
$181B
– –
-287,600
Closed -$17.8M
IMCR icon
136
Immunocore
IMCR
$1.63B
– –
-131,100
Closed -$4.89M
MIST icon
137
Milestone Pharmaceuticals
MIST
$113M
– –
-1,817,521
Closed -$11.2M
NTRA icon
138
CALL
Natera
NTRA
$50.2B
– –
-150,000
Closed -$5.32M
NVAX icon
139
CALL
Novavax
NVAX
$1.53B
– –
-75,000
Closed -$3.86M
REGN icon
140
Regeneron Pharmaceuticals
REGN
$79.9B
– –
-22,200
Closed -$13.1M
SGHT icon
141
Sight Sciences
SGHT
$447M
– –
-200,000
Closed -$1.8M
TBPH icon
142
Theravance Biopharma
TBPH
$885M
– –
-1,370,250
Closed -$12.4M
TRML
143
DELISTED
Tourmaline Bio
TRML
– –
-23,600
Closed -$1.06M
VTGN icon
144
VistaGen Therapeutics
VTGN
$10.6M
– –
-447,376
Closed -$11.8M
SONX
145
DELISTED
Sonendo, Inc.
SONX
– –
-723,478
Closed -$1.24M
NMTR
146
DELISTED
9 Meters Biopharma
NMTR
– –
-425,286
Closed -$2.22M
ISEE
147
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
– –
-1,361,400
Closed -$13.1M
APTX
148
DELISTED
Aptinyx Inc. Common Stock
APTX
– –
-538,500
Closed -$300K
SGFY
149
DELISTED
Signify Health, Inc.
SGFY
– –
-900,000
Closed -$12.4M
GBT
150
DELISTED
Global Blood Therapeutics, Inc.
GBT
– –
-2,044,000
Closed -$65.3M
3 4 5
6
7

Similar funds

MYIA
Mount Yale Investment Advisors Denver, Colorado $5.4B AUM 28.46% 1-Year Est. Return
SCM
Shelton Capital Management Denver, Colorado $5.39B AUM 56.42% 1-Year Est. Return
BJL
Brighton Jones LLC Seattle, Washington $5.38B AUM 27.31% 1-Year Est. Return
BG
Baupost Group Boston, Massachusetts $5.42B AUM 22.93% 1-Year Est. Return
SNT
SIG North Trading Bala Cynwyd, Pennsylvania $5.42B AUM 31.03% 1-Year Est. Return
NL
NEPC LLC Boston, Massachusetts $5.36B AUM 7.83% 1-Year Est. Return
RC
Resolution Capital Sydney, NSW, Australia $5.44B AUM 27.71% 1-Year Est. Return
AC
AlphaCore Capital La Jolla, California $5.44B AUM 26.35% 1-Year Est. Return

OrbiMed's Q3 2022 Portfolio in Review

As of Q3 2022, OrbiMed held 156 positions worth $5.39B, down 2.4% from $5.52B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

OrbiMed withdrew a net $296M in Q3 2022, closing 25 positions and reducing 31 holdings. Its most notable exit was Horizon Therapeutics Public Limited Company Ordinary Shares, an estimated $168M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 98% of assets, up from 98% a quarter earlier, followed by Miscellaneous.

Against the trend, OrbiMed opened a new position in Third Harmonic Bio worth $110M.

  • OrbiMed's largest Q3 2022 buy was Third Harmonic Bio: 5,779,071 shares worth $110M.
  • OrbiMed added most to Sarepta Therapeutics in Q3 2022, an estimated $90.6M increase.
  • OrbiMed's biggest Q3 2022 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $81.3M.
  • OrbiMed fully exited Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2022, selling an estimated $168M.
  • OrbiMed's ten largest holdings make up 31% of its $5.39B portfolio in Q3 2022.
  • OrbiMed opened 15 new positions and closed 25 in Q3 2022.
  • OrbiMed's portfolio value fell 2.4% quarter-over-quarter to $5.39B.

Based on OrbiMed's 13F filing for Q3 2022, filed 14 Nov 2022.